CCIA
PHAT icon

Campbell & Co Investment Adviser’s Phathom Pharmaceuticals PHAT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$746K Buy
68,759
+6,736
+11% +$76.9K 0.04% 650
2026
Q1 		$689K Sell
62,023
-53,261
-46% -$673K 0.04% 638
2025
Q4 		$1.91M Buy
+115,284
New +$1.65M 0.09% 342

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Campbell & Co Investment Adviser's PHAT Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Phathom Pharmaceuticals (PHAT) stake by 11% in Q2 2026, buying an estimated $76.9K and bringing the position to 68,759 shares worth $746K. The position accounts for 0.04% of the portfolio, ranked #650.

Campbell & Co Investment Adviser first reported a position in PHAT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.91M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Campbell & Co Investment Adviser held 68,759 shares of Phathom Pharmaceuticals worth $746K as of Q2 2026.
  • Campbell & Co Investment Adviser bought 6,736 Phathom Pharmaceuticals shares in Q2 2026, an estimated $76.9K.
  • Phathom Pharmaceuticals made up 0.04% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #650 holding.
  • Campbell & Co Investment Adviser first reported a position in Phathom Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Campbell & Co Investment Adviser's Phathom Pharmaceuticals position peaked at $1.91M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.